Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
View Patent ↗Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.
1. An isolated antibody that binds to an EGFR family member, wherein said antibody comprises a heavy chain variable domain (VH) comprising the three VH CDRs of the F5B6H2 antibody and/or a light chain variable domain (VL) comprising the three VL CDRs of the F5B6H2 antibody.
2. The antibody of claim 1 , wherein said antibody comprises a heavy chain variable domain (VH) of the F5B6H2 antibody and/or a light chain variable domain (VL) of the F5B6H2 antibody.
3. The antibody of claim 1 , wherein said antibody comprises a heavy chain variable domain (VH) comprising the three VH CDRs of the F5B6H2 antibody and a light chain variable domain (VL) comprising the three VL CDRs of the F5B6H2 antibody.
4. The antibody of claim 1 , wherein said antibody comprises a heavy chain variable domain (VH) of the F5B6H2 antibody and a light chain variable domain (VL) of the F5B6H2 antibody.
5. The antibody of claim 1 , wherein said antibody is an antibody selected from the group consisting of an scFv, an IgG, a Fab, an (Fab′) 2 , and an (scFv′) 2 .
6. The antibody of claim 1 , wherein said antibody is coupled to an effector.
7. The antibody claim 6 , wherein said effector comprises a second antibody.
8. The antibody of claim 6 , wherein said effector comprises a second antibody, wherein said second antibody comprises a heavy chain variable domain (VH) comprising the three VH CDRs and/or a light chain variable domain (VL) comprising the three VL CDRs of an antibody selected from the group consisting of A5, F5B6H2, C6.5, C6-B1D2, C6 MH3-B1, C6ML3-9, EGFR.B11, EGFR.C10, EGFR.1C10, EGFR.E12, EGFR.E8, F5, HER3.B12, HER3.E12, HER3.F4, HER3.H1, HER3.H3, HER4.B6, HER4.E3, and G98A.
9. The antibody of claim 8 , wherein said second antibody comprises a heavy chain variable domain (VH) comprising the three VH CDRs and a light chain variable domain (VL) comprising the three VL CDRs of an antibody selected from the group consisting of A5, F5B6H2, C6.5, C6-B1D2, C6 MH3-B1, C6ML3-9, EGFR.B11, EGFR.C10, EGFR.1C10, EGFR.E12, EGFR.E8, F5, HER3.B12, HER3.E12, HER3.F4, HER3.H1, HER3.H3, HER4.B6, HER4.E3, and G98A.
10. The antibody of claim 8 , wherein said second antibody comprises a heavy chain variable domain (VH) and/or a light chain variable domain (VL) of an antibody selected from the group consisting of A5, F5B6H2, C6.5, C6-B1D2, C6 MH3-B1, C6ML3-9, EGFR.B11, EGFR.C10, EGFR.1C10, EGFR.E12, EGFR.E8, F5, HER3.B12, HER3.E12, HER3.F4, HER3.H1, HER3.H3, HER4.B6, HER4.E3, and G98A.
11. The antibody of claim 8 , wherein said second antibody comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) of an antibody selected from the group consisting of A5, F5B6H2, C6.5, C6-B1D2, C6 MH3-B1, C6ML3-9, EGFR.B11, EGFR.C10, EGFR.1C10, EGFR.E12, EGFR.E8, F5, HER3.B12, HER3.E12, HER3.F4, HER3.H1, HER3.H3, HER4.B6, HER4.E3, and G98A.
12. The antibody of claim 8 , wherein said second antibody is joined to the first antibody by a linker.
13. The antibody of claim 12 , wherein said linker is a peptide linker.
14. The antibody of claim 12 , wherein said linker is a peptide linker that lacks a proteolytic cleavage site.
15. The antibody of claim 1 , wherein said antibody is combined with a pharmaceutically acceptable excipient.
16. An isolated nucleic acid that encodes an isolated antibody that binds to an EGFR family member, wherein said antibody comprises a heavy chain variable domain (VH) comprising the three VH CDRs of the F5B6H2 antibody and/or a light chain variable domain (VL) comprising the three VL CDRs of the F5B6H2 antibody.
17. A vector comprising the nucleic acid sequence of claim 16 .
18. A host cell transfected with a nucleic acid that encodes an antibody comprising a heavy chain variable domain (VH) comprising the three VH CDRs of the F5B6H2 antibody and/or a light chain variable domain (VL) comprising the three VL CDRs of the F5B6H2 antibody.